• Primidone: A Translational Assay Strategy

  2026-08-24

  Primidone, also known as Mysoline, is best evaluated through mechanism-specific assays rather than a single pharmacology readout. This guide connects its TRPM3 and RIPK1 research applications with lessons from LL-37 antibiofilm testing while clearly defining the evidence boundaries between neuroscience and infection research.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-08-24

  Zhao and colleagues present a standardized whole-blood stimulation protocol that combines defined immune challenges with pharmacological metabolism modulation and cytokine measurement. The workflow helps distinguish pathway-specific effects on immune activation while offering a practical framework for reproducible cohort studies and mechanistic immunometabolism research.

• O-GlcNAcylation Rewires Wnt-Driven Bone Formation

  2026-08-23

  The reference study identifies O-GlcNAcylation as a metabolic and post-translational mechanism that connects Wnt3a signaling with aerobic glycolysis and osteoblastogenesis. Its findings place PDK1 Ser174 modification downstream of a biphasic Ca2+-PKA-GFAT1 and Wnt–β-catenin response, offering a framework for testing how signaling and glucose metabolism cooperate during bone formation.

• Copper–Hexetidine Synergy in Oral Streptococci

  2026-08-22

  Grytten, Scheie, and Giertsen showed that copper sulfate and hexetidine produced strong synergistic growth inhibition against Streptococcus sobrinus and Streptococcus sanguis. The study combined fractional inhibitory concentration analysis with growth curves, offering a compact experimental model for distinguishing true combination effects from simple additive antibacterial activity.

• Sulforaphane, Oxidative Stress, and NLRP3 in Colitis

  2026-08-22

  A 2024 study in Biomedicine & Pharmacotherapy used dextran sodium sulfate-induced colitis and macrophage experiments to connect sulforaphane-mediated ROS reduction with suppression of NLRP3 inflammasome signaling. The findings clarify a redox-sensitive inflammatory mechanism while also defining the limits of translating mouse and cell-culture results into ulcerative colitis therapy.

• Viscosity-Driven P-gp Chemoresistance in Cancer

  2026-08-21

  Zhou, Wu, and Zhang show that tumor-like extracellular fluid viscosity can induce doxorubicin resistance by linking cytoskeletal remodeling and membrane tension to TRPV4–YAP signaling and P-gp (ABCB1) upregulation. The work shifts attention from biochemical cues alone to viscosity as a mechanobiological determinant of drug response and suggests that reducing tumor viscosity merits testing as a resistance-mitigating strategy.

• Erastin: Practical Ferroptosis Research Workflows

  2026-08-20

  Use Erastin as a mechanistic ferroptosis inducer for genotype-aware tumor-cell studies, oxidative stress assays, and benchmarking of targeted nanotherapies. This guide connects reproducible handling with multi-readout workflows inspired by a recent folate receptor-directed pancreatic cancer study.

• Nystatin (Fungicidin): From Mechanism to Translation

  2026-08-20

  Nystatin (Fungicidin) is more than a conventional polyene comparator: its ergosterol-directed mechanism creates a platform for studying membrane vulnerability, resistance biology, formulation strategy, and combination antifungal development. This article connects mechanistic evidence with practical assay design and translational decision-making across Candida and Aspergillus research.

• Polymyxin B and the LPS–Immunotherapy Axis

  2026-08-19

  Polymyxin B sulfate sits at the intersection of membrane disruption, innate immune signaling, and translational infection research. New evidence shows that the structure of microbiota-derived LPS can influence anti-PD-1 responses, creating a strategic opportunity to use Polymyxin B as a carefully controlled mechanistic perturbation—not as an assumed immunotherapy adjuvant.

• SR 11302: AP-1 Transcription Factor Inhibitor Workflows

  2026-08-19

  SR 11302 enables selective AP-1 pathway interrogation in tumor-cell, chemoprevention, and macrophage-polarization workflows without the receptor activation associated with retinoids. This practical guide covers assay setup, dose selection, pathway controls, formulation, and troubleshooting for reproducible cancer research.

• 2-NBDG for Mechanistic Glucose Uptake Studies

  2026-08-18

  2-NBDG enables cell-resolved glucose uptake measurements, but its greatest value emerges when uptake data are connected to glycolytic mechanisms. This article develops an assay strategy for interpreting 2-NBDG signals in PXDN–LDHA glioblastoma research while distinguishing transport from downstream metabolic flux.

• Brain-to-Spinal Circuits in Mechanical Allodynia

  2026-08-18

  Huo et al. identify a contralateral lPBN Oprm1–dmH Pdyn–spinal dorsal horn pathway that regulates both the laterality and persistence of mechanical allodynia in mice. Their loss- and gain-of-function experiments connect hypothalamic dynorphin and spinal κ-opioid receptor signaling to bilateral pain control, offering a circuit framework for opioid receptor pharmacology and pain modulation research.

• 8-Chloroadenosine RNA Research Workflows

  2026-08-17

  Use 8-Chloroadenosine as a controllable RNA synthesis perturbation in transcriptional regulation research, RNA turnover experiments, and cancer research. This guide translates a recent NSCLC lncRNA study into practical assay designs while clarifying where this nucleoside analog complements, rather than replaces, targeted genetic or transcriptional controls.

• Fluorouracil (Adrucil): Mechanism & Benchmarks

  2026-08-17

  Fluorouracil, also called 5-Fluorouracil, inhibits thymidylate synthase after conversion to FdUMP and thereby disrupts dTMP production. Product-reported benchmarks include a 2.5 μM IC50 in HT-29 colon carcinoma cells and tumor-growth inhibition at 100 mg/kg intraperitoneally once weekly in a murine colon carcinoma model.

• (-)-Blebbistatin in Cardiac Optogenetic Assays

  2026-08-16

  (-)-Blebbistatin can serve as a reversible non-muscle myosin II inhibitor for separating electrical activity from motion in cardiac optogenetic experiments. This guide explains how to use the compound as a mechanistic perturbation while interpreting panoramic optical and electrical measurements responsibly.

8372 records 2/559 page Previous Next 12345 下5页 Last page